Sangamo Therapeutics Inc (SGMO) Com Stk USD0.01

Sell:$0.54Buy:$0.54$0.01 (0.94%)

Prices delayed by at least 15 minutes
Sell:$0.54
Buy:$0.54
Change:$0.01 (0.94%)
Prices delayed by at least 15 minutes
Sell:$0.54
Buy:$0.54
Change:$0.01 (0.94%)
Prices delayed by at least 15 minutes

Company Information

About this company

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Key people

Alexander D. Macrae
President, Chief Executive Officer, Director
Prathyusha Duraibabu
Chief Financial Officer, Senior Vice President
Gregory Davis
Head of Research & Technology
Nathalie Dubois- Stringfellow
Chief Development Officer
Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
H. Stewart Parker
Independent Chairman of the Board
Courtney Beers
Independent Director
Robert F. Carey
Independent Director
Kenneth J. Hillan
Independent Director
Margaret A. Horn
Independent Director
Click to see more

Key facts

  • EPIC
    SGMO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8006771062
  • Market cap
    $128.52m
  • Employees
    183
  • Shares in issue
    237.60m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.